Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R 1 is H, -OH, C 1-6 alkoxy, -NR 5 R 6 , or Sac 1； R 2 is H, -OH, C 1-6 alkoxy or Sac 2； R 3 is H, -OH, C 1-6 alkoxy or Sac 3； R 4 is H, C 1-6 alkyl, C 1-6 hydroxyalkyl or C 1-6 -alkoxy-C 1-6 -alkyl； R 5 is H, C 1-6 alkyl or C 1-6 acyl； R 6 is H, C 1-6 alkyl or C 1-6 acyl； Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties； and Z is a steroid moiety； or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition to be treated is an inflammatory condition selected from ileitis, cholitis, cholecystitis, diverticulitis, gastritis, irritable bowel syndrome, inflammatory bowel disease, Lupus and ulcerative cholitis.
